Literature DB >> 16545608

Defective translation initiation causes vanishing of cerebral white matter.

Gert C Scheper1, Christopher G Proud, Marjo S van der Knaap.   

Abstract

Leukoencephalopathy with vanishing white matter (VWM) is one of the most prevalent inherited white-matter disorders, especially in Caucasian populations. VWM is unusual because of its sensitivity to febrile infections and minor head trauma. The basic defect of this enigmatic brain disease resides in the regulation of initiation of protein synthesis. Recently, undue activation of the unfolded-protein response has emerged as an important factor in the pathophysiology of VWM. Here, we discuss the mechanisms that might be responsible for the selective involvement of the brain white matter in VWM. At present, VWM research is in need of an animal model to study disease mechanisms and therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545608     DOI: 10.1016/j.molmed.2006.02.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  13 in total

1.  Impaired eukaryotic translation initiation factor 2B activity specifically in oligodendrocytes reproduces the pathology of vanishing white matter disease in mice.

Authors:  Yifeng Lin; Xiaosha Pang; Guangcun Huang; Stephanie Jamison; Jingye Fang; Heather P Harding; David Ron; Wensheng Lin
Journal:  J Neurosci       Date:  2014-09-03       Impact factor: 6.167

2.  Similarities and differences between infantile and early childhood onset vanishing white matter disease.

Authors:  Ling Zhou; Haihua Zhang; Na Chen; Zhongbin Zhang; Ming Liu; Lifang Dai; Jingmin Wang; Yuwu Jiang; Ye Wu
Journal:  J Neurol       Date:  2018-04-16       Impact factor: 4.849

Review 3.  Regulation and function of elF2B in neurological and metabolic disorders.

Authors:  Filipe M Hanson; Rachel E Hodgson; Madalena I Ribeiro de Oliveira; K Elizabeth Allen; Susan Gerarda Campbell
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

4.  ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.

Authors:  Morgan A Sammons; Amanda K Antons; Mourad Bendjennat; Bjarne Udd; Ralf Krahe; Andrew J Link
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

5.  Astrocytes are central in the pathomechanisms of vanishing white matter.

Authors:  Stephanie Dooves; Marianna Bugiani; Nienke L Postma; Emiel Polder; Niels Land; Stephen T Horan; Anne-Lieke F van Deijk; Aleid van de Kreeke; Gerbren Jacobs; Caroline Vuong; Jan Klooster; Maarten Kamermans; Joke Wortel; Maarten Loos; Lisanne E Wisse; Gert C Scheper; Truus E M Abbink; Vivi M Heine; Marjo S van der Knaap
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

6.  Adenosine deaminase ADAR1 increases gene expression at the translational level by decreasing protein kinase PKR-dependent eIF-2alpha phosphorylation.

Authors:  Ying Wang; Charles E Samuel
Journal:  J Mol Biol       Date:  2009-09-03       Impact factor: 5.469

7.  Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder.

Authors:  A Vanderver; Y Hathout; J Maletkovic; E S Gordon; M Mintz; M Timmons; E P Hoffman; L Horzinski; F Niel; A Fogli; O Boespflug-Tanguy; R Schiffmann
Journal:  Neurology       Date:  2008-06-03       Impact factor: 9.910

8.  PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases.

Authors:  Yifeng Lin; Guangcun Huang; Stephanie Jamison; Jin Li; Heather P Harding; David Ron; Wensheng Lin
Journal:  Am J Pathol       Date:  2013-11-19       Impact factor: 4.307

Review 9.  Myelin under stress.

Authors:  Maurizio D'Antonio; M Laura Feltri; Lawrence Wrabetz
Journal:  J Neurosci Res       Date:  2009-11-15       Impact factor: 4.164

Review 10.  The unfolded protein response in multiple sclerosis.

Authors:  Sarrabeth Stone; Wensheng Lin
Journal:  Front Neurosci       Date:  2015-07-29       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.